I'm LongbridgeAI, I can summarize articles.Q2 2026 revenue reached $47.3 million with gross margin expanding to 89%, while adjusted EBITDA loss improved sequentially. Active subscribers grew 20% year-over-year, and the transition to branded GLP-1 therapies is complete. Full-year guidance was revised downward, but positive adjusted EBITDA is expected in the second half.Original document: LifeMD, Inc. [LFMD] SEC 8-K Current Report — Aug. 5 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 revenue reached $47.3 million with gross margin expanding to 89%, while adjusted EBITDA loss improved sequentially. Active subscribers grew 20% year-over-year, and the transition to branded GLP-1 therapies is complete. Full-year guidance was revised downward, but positive adjusted EBITDA is expected in the second half.
Original document: LifeMD, Inc. [LFMD] SEC 8-K Current Report — Aug. 5 2026